Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Janux Therapeutics Inc (NASDAQ: JANX) closed the day trading at $27.46 down -3.72% from the previous closing price of $28.52. In other words, the price has decreased by -$3.72 from its previous closing price. On the day, 0.79 million shares were traded. JANX stock price reached its highest trading level at $28.68 during the session, while it also had its lowest trading level at $26.96.
Ratios:
For a better understanding of JANX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 35.86 and its Current Ratio is at 35.86. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $47.
On September 10, 2025, Truist started tracking the stock assigning a Buy rating and target price of $100.
On September 10, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $45.Stifel initiated its Buy rating on September 10, 2025, with a $45 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 28 ’25 when Meyer Andrew Hollman sold 16,665 shares for $30.06 per share. The transaction valued at 500,987 led to the insider holds 82,139 shares of the business.
ANDREW MEYER bought 16,665 shares of JANX for $455,788 on Oct 28 ’25. On May 01 ’25, another insider, Meyer Andrew Hollman, who serves as the Chief Business Officer of the company, sold 3,333 shares for $32.03 each. As a result, the insider received 106,745 and left with 82,139 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1651658752 and an Enterprise Value of 685325760. For the stock, the TTM Price-to-Sale (P/S) ratio is 165.17 while its Price-to-Book (P/B) ratio in mrq is 1.69. Its current Enterprise Value per Revenue stands at 68.533 whereas that against EBITDA is -4.819.
Stock Price History:
The Beta on a monthly basis for JANX is 2.83, which has changed by -0.41509432 over the last 52 weeks, in comparison to a change of 0.1476624 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $21.73. The 50-Day Moving Average of the stock is 7.67%, while the 200-Day Moving Average is calculated to be 0.35%.
Shares Statistics:
Over the past 3-months, JANX traded about 918.00K shares per day on average, while over the past 10 days, JANX traded about 1075900 shares per day. A total of 60.12M shares are outstanding, with a floating share count of 54.36M. Insiders hold about 9.62% of the company’s shares, while institutions hold 110.43% stake in the company. Shares short for JANX as of 1761868800 were 6946508 with a Short Ratio of 7.57, compared to 1759190400 on 8932119. Therefore, it implies a Short% of Shares Outstanding of 6946508 and a Short% of Float of 16.600001.
Earnings Estimates
As of right now, 10.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.56 and low estimates of -$1.19.
Analysts are recommending an EPS of between -$1.78 and -$2.56 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is -$3.17, with 13.0 analysts recommending between -$2.38 and -$5.5.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for JANX’s current fiscal year. The highest revenue estimate was $10M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $10M. In the same quarter a year ago, actual revenue was $10.59M
